Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism
暂无分享,去创建一个
[1] B. Nieswandt,et al. Platelet adhesion and activation mechanisms in arterial thrombosis and ischaemic stroke , 2011, Journal of thrombosis and haemostasis : JTH.
[2] J. Nunnelee. Review of an article: oral rivaroxaban for symptomatic venous thromboembolism. The EINSTEIN Investigators et al. N Engl J Med 2010; 363(26):2499-2510. , 2011, Journal of vascular nursing : official publication of the Society for Peripheral Vascular Nursing.
[3] Kenneth A Ellenbogen,et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on Dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2011, Circulation.
[4] Jun Zhu,et al. Apixaban in patients with atrial fibrillation. , 2011, The New England journal of medicine.
[5] B. Eriksson,et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II) , 2011, Thrombosis and Haemostasis.
[6] R. P. Zhu,et al. Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation , 2011, Annals of Internal Medicine.
[7] T. Lindahl,et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays , 2011, Journal of thrombosis and haemostasis : JTH.
[8] G. Raskob,et al. Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis , 2011, Journal of thrombosis and haemostasis : JTH.
[9] Bruce L Davidson,et al. Oral rivaroxaban for symptomatic venous thromboembolism. , 2010, The New England journal of medicine.
[10] G. Raskob,et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. , 2010, The New England journal of medicine.
[11] M. Gent,et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty , 2010, Thrombosis and Haemostasis.
[12] S. Yusuf,et al. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial , 2010, The Lancet Neurology.
[13] T. Ortel,et al. Assays for Measuring Rivaroxaban: Their Suitability and Limitations , 2010, Therapeutic drug monitoring.
[14] T. Lindahl,et al. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays , 2010, Thrombosis and Haemostasis.
[15] S. Yusuf,et al. Newly identified events in the RE-LY trial. , 2010, The New England journal of medicine.
[16] A. Shenker,et al. Clinical laboratory measurement of direct factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assay , 2010, Thrombosis and Haemostasis.
[17] F. Gao,et al. Apixaban versus enoxaparin in patients with total knee arthroplasty , 2010, Thrombosis and Haemostasis.
[18] Jeroen J. Bax,et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). , 2010, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[19] E. Antman,et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). , 2010, American heart journal.
[20] A. Camm,et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). , 2010, European heart journal.
[21] Salim Yusuf,et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial , 2010, The Lancet.
[22] C. Francis,et al. Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials. , 2010, Thrombosis research.
[23] H. Masumoto,et al. Clinical Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Factor Xa Inhibitor Edoxaban in Healthy Volunteers , 2010, Journal of clinical pharmacology.
[24] P. Cortez,et al. Reversibility of the anti‐FXa activity of idrabiotaparinux (biotinylated idraparinux) by intravenous avidin infusion , 2010, Journal of thrombosis and haemostasis : JTH.
[25] M. Feuring,et al. Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity , 2010, Thrombosis and Haemostasis.
[26] G. Raskob,et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial , 2010, The Lancet.
[27] S. Yusuf,et al. Dabigatran Versus Warfarin in Patients With Atrial Fibrillation: An Analysis of Patients Undergoing Cardioversion , 2010, Circulation.
[28] B. Gersh,et al. Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. , 2010, American heart journal.
[29] V. Laux,et al. Rivaroxaban: A New Oral Factor Xa Inhibitor , 2010, Arteriosclerosis, thrombosis, and vascular biology.
[30] S. Goldhaber,et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. , 2009, The New England journal of medicine.
[31] G. Raskob,et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. , 2009, The New England journal of medicine.
[32] S. Yusuf,et al. Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.
[33] J. Harenberg. Development of idraparinux and idrabiotaparinux for anticoagulant therapy , 2009, Thrombosis and Haemostasis.
[34] T. Lüscher,et al. Novel anticoagulants in clinical development: focus on factor Xa and direct thrombin inhibitors , 2009, Journal of cardiovascular medicine.
[35] J. Mega,et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial , 2009, The Lancet.
[36] Deepak L. Bhatt,et al. Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome: Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) Trial , 2009, Circulation.
[37] M. Gent,et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial , 2009, The Lancet.
[38] P. Wong,et al. Apixaban, an oral direct factor Xa inhibitor, inhibits human clot-bound factor Xa activity in vitro , 2009, Thrombosis and Haemostasis.
[39] A. Tripodi,et al. Laboratory monitoring of anticoagulation: where do we stand? , 2009, Seminars in thrombosis and hemostasis.
[40] W. Humphreys,et al. Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans , 2009, Drug Metabolism and Disposition.
[41] David J. Gladstone,et al. Potentially Preventable Strokes in High-Risk Patients With Atrial Fibrillation Who Are Not Adequately Anticoagulated , 2009, Stroke.
[42] M. Prins,et al. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose‐ranging study , 2008, Journal of thrombosis and haemostasis : JTH.
[43] Bengt I Eriksson,et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial , 2008, The Lancet.
[44] W. Ageno,et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. , 2008, The New England journal of medicine.
[45] B. Eriksson,et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. , 2008, The New England journal of medicine.
[46] G. Guyatt,et al. Antithrombotic and thrombolytic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.
[47] P. Lam,et al. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies , 2008, Journal of thrombosis and haemostasis : JTH.
[48] P. Prandoni,et al. Idraparinux: review of its clinical efficacy and safety for prevention and treatment of thromboembolic disorders , 2008, Expert opinion on investigational drugs.
[49] S. Frostick,et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE‐MODEL randomized trial , 2007, Journal of thrombosis and haemostasis : JTH.
[50] S. Frostick,et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial , 2007, The Lancet.
[51] K. Rathgen,et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. , 2007, British journal of clinical pharmacology.
[52] M. Aguilar,et al. Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation , 2007, Annals of Internal Medicine.
[53] Salim Yusuf,et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. , 2006, The New England journal of medicine.
[54] S. Yusuf,et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. , 2006, JAMA.
[55] T. Lüscher,et al. Tissue Factor in Cardiovascular Diseases: Molecular Mechanisms and Clinical Implications , 2006, Circulation.
[56] Mark Crowther,et al. Systematic overview of warfarin and its drug and food interactions. , 2005, Archives of internal medicine.
[57] K. Schlemmer,et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59‐7939—an oral, direct Factor Xa inhibitor , 2005, Journal of thrombosis and haemostasis : JTH.
[58] J. Hirsh,et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.
[59] M. Schenone,et al. The blood coagulation cascade , 2004, Current opinion in hematology.
[60] A. Wittkowsky. Warfarin and Other Coumarin Derivatives: Pharmacokinetics, Pharmacodynamics, and Drug Interactions , 2003, Seminars in vascular medicine.
[61] George Davey Smith,et al. Meta-analysis of randomised controlled trials , 1997, The Lancet.
[62] T. Andersson,et al. Drug-induced liver injury in humans: the case of ximelagatran. , 2010, Handbook of experimental pharmacology.
[63] G. Raskob,et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. , 2009, The Journal of arthroplasty.
[64] J. Stangier. Clinical Pharmacokinetics and Pharmacodynamics of the Oral Direct Thrombin Inhibitor Dabigatran Etexilate , 2008, Clinical pharmacokinetics.
[65] R. O'Reilly,et al. Warfarin metabolism and drug-drug interactions. , 1987, Advances in experimental medicine and biology.